Reducing attrition in drug development: smart loading preclinical safety assessment
Ruth A Roberts1, Stefan L Kavanagh1, Howard R Mellor1
1Drug Safety and Metabolism, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, UK.
Abstract:
Entry into the crucial preclinical good laboratory practice (GLP) stage of toxicology testing triggers significant R&D investment yet >20% of AstraZeneca's potential new medicines have been stopped for safety reasons in this GLP phase alone. How could we avoid at least some of these costly failures? An analysis of historical toxicities that caused stopping ('stopping toxicities') showed that >50% were attributable to target organ toxicities emerging within 2 weeks of repeat dosing or to acute cardiovascular risks. By frontloading 2-week repeat-dose toxicity studies and a comprehensive assessment of cardiovascular safety, we anticipate a potential 50% reduction in attrition in the GLP phase. This will reduce animal use overall, save significant R&D costs and improve drug pipeline quality.
More Related Videos
Related Concept Videos
Preclinical Development: Overview
Drug Discovery: Overview
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Bioavailability Study Design: Healthy Subjects Versus Patients
Clinical Trials: Overview
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...


